Brief questions to identify patients with inadequate health literacy.
Lisa D Chew, Katharine A Bradley, Edward J Boyko
https://pubmed.ncbi.nlm.nih.gov/15343421/Actively Recruiting
Led by Hackensack Meridian Health · Updated on 2026-09-08
100
Participants Needed
10
Research Sites
N/A
Total Duration
Researchers are conducting a pilot Type 1 Hybrid Effectiveness-Implementation Trial to evaluate a tailored lung screening intervention in patients at risk for lung cancer. The study focuses on using an Electronic Health Record-embedded Social Determinants of Health SDoH screening tool in the Emergency Department to identify eligible patients and increase lung cancer screening uptake. The trial aims to assess the reach and preliminary effectiveness of this intervention in comparison with enhanced usual care by examining factors such as health literacy, mistrust, stigma, fatalism, knowledge, and lung screening health beliefs. The study compares two groups one receiving LungTalk, a tailored, interactive educational program delivered via iPad that adapts content based on smoking status and perceived barriers and another receiving a non-tailored lung screening pamphlet emailed to patients along with patient navigation support. LungTalk includes audio, video, and animation to engage participants, while the pamphlet provides standard educational information about lung cancer risk and screening. Participants are identified through SDoH screening and receive tailored or standard educational materials accordingly. Participants aged 50 to 80 who currently smoke or quit within 15 years and have a 20 pack-year smoking history are involved. Researchers will measure lung cancer screening uptake and stage of adoption at 1 week, 1 month, and 6 months post-intervention. Additional assessments include health literacy, medical mistrust, stigma, perceived risk, benefits and barriers to screening, self-efficacy, knowledge, and fatalism at 1 week and 1 month. The study uses randomized methods and collects data from electronic health records to monitor outcomes and reach over the trial period.
CONDITIONS
Leveraging the Emergency Department (LEAD) Study
A
Ana Guadalupe Vielma, PhD
F
Francis Valenzona
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Hackensack Meridian Health
Lead Sponsor
New Jersey Commission on Cancer Research
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | LungTalk tailored intervention | Non‑tailored education + navigation | LDCT screening (standard care) |
|---|---|---|---|
| What it is | A tailored educational intervention (‘LungTalk’) combined with social determinants of health (SDOH) screening and patient navigation to promote lung cancer screening uptake. | A non‑tailored lung screening educational pamphlet plus SDOH screening and patient navigation. | Annual lung cancer screening with low‑dose CT as recommended for similar high‑risk adults. |
| Role in trial | Experimental arm delivering a tailored behavioral intervention. | Active comparator arm using non‑tailored educational materials. | Represents current guideline‑recommended screening method not tested in trial. |
| Primary use | Encourage uptake of guideline‑recommended lung cancer screening in eligible adults. | Encourage lung cancer screening via non‑tailored education and navigation. | Annual LDCT is used to detect lung cancer early in high‑risk individuals. |
| How it is given or performed | Delivered tailored messaging using LungTalk plus SDOH screening and navigation contacts. | Sent standard educational brochure via email, followed by navigation contact within 48 hours. | Performed as a low‑dose chest CT scan annually. |
| Evidence status | Efficacy under investigation; trial to assess if tailored messaging improves screening uptake. | Effectiveness under study as comparison to the tailored approach. | Proven to reduce lung cancer mortality in eligible high‑risk adults. |
| Limitations | Effect on actual screening uptake and long‑term adherence is yet to be determined. | May be less engaging or effective than tailored messaging. | Requires access to screening facilities and may involve screening harms noted above. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or remote)
Duration - 1 month
Participants receive either the LungTalk tailored educational program via iPad or a non-tailored lung screening pamphlet via email with patient navigation support.
1 baseline visit and follow-up contacts
Duration - 6 months
Researchers track lung cancer screening uptake and adoption stage at 1 week, 1 month, and 6 months after the intervention. Additional surveys assess health literacy, mistrust, stigma, risk perception, benefits, barriers, self-efficacy, knowledge, and fatalism.
Follow-up assessments at 1 week, 1 month, and 6 months
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SCREENING
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Lisa D Chew, Katharine A Bradley, Edward J Boyko
https://pubmed.ncbi.nlm.nih.gov/15343421/Pamela Hallquist Viale
https://pubmed.ncbi.nlm.nih.gov/33532112/Mack T Ruffin, Michael D Fetters, Masahito Jimbo
https://pubmed.ncbi.nlm.nih.gov/17689600/Yan Kwan Lau, Tanner J Caverly, Sarah T Cherng...
https://pubmed.ncbi.nlm.nih.gov/25532218/Akke Albada, Margreet G E M Ausems, Jozien M Bensing...
https://pubmed.ncbi.nlm.nih.gov/19376676/National Lung Screening Trial Research Team, Denise R Aberle, Amanda M Adams...
https://pubmed.ncbi.nlm.nih.gov/21714641/Lisa Carter-Harris, Lynne A Hall
https://pubmed.ncbi.nlm.nih.gov/25157591/Lisa Carter-Harris, Lorie L Davis, Susan M Rawl
https://pubmed.ncbi.nlm.nih.gov/28304262/Lisa Carter-Harris, James E Slaven, Patrick O Monahan...
https://pubmed.ncbi.nlm.nih.gov/29552458/Susan M Rawl, Celette Sugg Skinner, Susan M Perkins...
https://pubmed.ncbi.nlm.nih.gov/22926008/Hackensack Meridian Health
Lead Sponsor
New Jersey Commission on Cancer Research
Collaborating Sponsor